CD19 and cancer: To date, FT596, a muti-targeting CAR-NK cell which possesses anti-CD19 CAR, non-cleavable CD16 receptor, and IL15/IL-15α was developed to enhance cancer-killing ability and improve the persistence of CAR-NK cells (22).